Published in Ophthalmology on December 01, 2000
Quantifying the benefits of additional channels of multifocal VEP recording. Doc Ophthalmol (2002) 1.57
Normative ranges and specificity of the multifocal VEP. Doc Ophthalmol (2004) 1.52
A signal-to-noise analysis of multifocal VEP responses: an objective definition for poor records. Doc Ophthalmol (2002) 1.45
Multifocal visual evoked potential and automated perimetry abnormalities in strabismic amblyopes. J AAPOS (2007) 1.45
Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol (2008) 1.12
Determining abnormal interocular latencies of multifocal visual evoked potentials. Doc Ophthalmol (2004) 1.05
Intertest variability of mfVEP amplitude: reducing its effect on the interpretation of sequential tests. Doc Ophthalmol (2006) 0.98
Objective perimetry using the multifocal visual evoked potential in central visual pathway lesions. Br J Ophthalmol (2005) 0.90
Multifocal visual-evoked potential in unilateral compressive optic neuropathy. Br J Ophthalmol (2006) 0.89
Optimal conditions for multifocal VEP recording for normal Japanese population established by receiver operating characteristic analysis. Doc Ophthalmol (2010) 0.85
Electrophysiological examination in uveitis: a review of the literature. Clin Ophthalmol (2014) 0.84
Topography of the chromatic pattern-onset VEP. J Vis (2003) 0.84
Effect of stimulus check size on multifocal visual evoked potentials. Doc Ophthalmol (2003) 0.83
Receiver-operating characteristic analysis of multifocal VEPs to diagnose and quantify glaucomatous functional damage. Doc Ophthalmol (2011) 0.83
Novel electrophysiological instrument for rapid and objective assessment of magnocellular deficits associated with glaucoma. Doc Ophthalmol (2008) 0.83
A method to detect progression of glaucoma using the multifocal visual evoked potential technique. Doc Ophthalmol (2008) 0.82
Influence of pupil size and other test variables on visual function assessment using visual evoked potentials in normal subjects. Doc Ophthalmol (2010) 0.80
The effect of eccentricity on the contrast response function of multifocal visual evoked potentials (mfVEPs). Vision Res (2009) 0.78
Multifocal VEP in children: its maturation and clinical application. Br J Ophthalmol (2004) 0.78
Effect of eccentricity on pattern-pulse multifocal VEP. Doc Ophthalmol (2005) 0.78
Effect of refractive errors on multifocal VEP responses and standard automated perimetry tests in a single population. Doc Ophthalmol (2014) 0.78
Study for analysis of the multifocal visual evoked potential. Korean J Ophthalmol (2011) 0.77
Physiological evidence for impairment in autosomal dominant optic atrophy at the pre-ganglion level. Graefes Arch Clin Exp Ophthalmol (2012) 0.77
Effect of recording duration on the diagnostic performance of multifocal visual-evoked potentials in high-risk ocular hypertension and early glaucoma. J Glaucoma (2008) 0.77
Improving the quality of multifocal visual evoked potential results by calculating multiple virtual channels. Jpn J Ophthalmol (2011) 0.77
Diagnostic value of multifocal VEP using cross-validation and noise reduction in glaucoma research. Graefes Arch Clin Exp Ophthalmol (2004) 0.76
Objective visual field determination in forensic ophthalmology with an optimized 4-channel multifocal VEP perimetry system: a case report of a patient with retinitis pigmentosa. Doc Ophthalmol (2011) 0.76
Visual evoked potential and psychophysical contrast thresholds in glaucoma. Doc Ophthalmol (2014) 0.76
Clinical use of multifocal visual-evoked potentials in a glaucoma practice: a prospective study. Doc Ophthalmol (2012) 0.75
Frequency-doubling technology perimetry and multifocal visual evoked potential in glaucoma, suspected glaucoma, and control patients. Clin Ophthalmol (2014) 0.75
Evaluation of hemifield sector analysis protocol in multifocal visual evoked potential objective perimetry for the diagnosis and early detection of glaucomatous field defects. Korean J Ophthalmol (2014) 0.75
All in the timing. Br J Ophthalmol (2007) 0.75
Reproducibility in the global indices for multifocal visual evoked potentials and Humphrey visual fields in controls and glaucomatous eyes within a 2-year period. Doc Ophthalmol (2015) 0.75
Steady-state multifocal visual evoked potential (ssmfVEP) using dartboard stimulation as a possible tool for objective visual field assessment. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Multifocal examination techniques in malingering: case report of a patient with monocular vertical hemianopia. Graefes Arch Clin Exp Ophthalmol (2002) 0.75
Multifocal visual evoked responses to dichoptic stimulation using virtual reality goggles: Multifocal VER to dichoptic stimulation. Doc Ophthalmol (2006) 0.75
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med (1995) 2.99
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 2.60
Central corneal thickness, tonometry, and ocular dimensions in glaucoma and ocular hypertension. J Glaucoma (2001) 2.43
Ability of the heidelberg retina tomograph to detect early glaucomatous visual field loss. J Glaucoma (1995) 2.30
Multifocal topographic visual evoked potential: improving objective detection of local visual field defects. Invest Ophthalmol Vis Sci (1998) 1.64
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res (2001) 1.46
Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol (1994) 1.26
Flash and pattern electroretinogram changes with optic atrophy and glaucoma. Exp Eye Res (1995) 1.18
Electroencephalogram-based scaling of multifocal visual evoked potentials: effect on intersubject amplitude variability. Invest Ophthalmol Vis Sci (2001) 1.11
Intertest variability of mfVEP amplitude: reducing its effect on the interpretation of sequential tests. Doc Ophthalmol (2006) 0.98
HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity. J Med Chem (1992) 0.96
Comparison of the Humphrey swedish interactive thresholding algorithm (SITA) and full threshold strategies. J Glaucoma (2000) 0.94
Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation (1997) 0.93
Comparison of objective diagnostic tests in glaucoma: Heidelberg retinal tomography and multifocal visual evoked potentials. J Glaucoma (2006) 0.91
Objective perimetry using the multifocal visual evoked potential in central visual pathway lesions. Br J Ophthalmol (2005) 0.90
Early magnocellular loss in glaucoma demonstrated using the pseudorandomly stimulated flash visual evoked potential. J Glaucoma (1999) 0.89
Multifocal pattern electroretinogram does not demonstrate localised field defects in glaucoma. Doc Ophthalmol (2000) 0.89
Closure of fornix-based posttrabeculectomy conjunctival wound leaks with autologous fibrin glue. Am J Ophthalmol (1992) 0.88
Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem Suppl (1995) 0.87
Atrial myxoma with multiple myeloma. Arch Intern Med (1979) 0.87
Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679. J Med Chem (1991) 0.86
Incomplete Reiter's syndrome with focal involvement of the posterior segment. Aust N Z J Ophthalmol (1995) 0.86
Selective reduction of oscillatory potentials and pattern electroretinograms after retinal ganglion cell damage by disease in humans or by kainic acid toxicity in cats. Doc Ophthalmol (1991) 0.85
Farnesyltransferase inhibitors versus Ras inhibitors. Curr Opin Chem Biol (1997) 0.85
Teratogenic potential of purified pentachlorophenol and pentachloroanisole in subchronically exposed Sprague-Dawley rats. Food Chem Toxicol (1987) 0.85
Electrode position and the multi-focal visual-evoked potential: role in objective visual field assessment. Aust N Z J Ophthalmol (1998) 0.83
Contrast sensitivity for flickering and static letters and visual acuity at isoluminance in glaucoma. J Glaucoma (1996) 0.83
Multifocal pattern VEP perimetry: analysis of sectoral waveforms. Doc Ophthalmol (1999) 0.83
Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat (1996) 0.81
Variability of mouse bioassay for determination of paralytic shellfish poisoning toxins. J Assoc Off Anal Chem (1986) 0.81
Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics. Biochem Soc Trans (1996) 0.80
Methods of treating plantar ulcers. Phys Ther (1991) 0.80
Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase. J Am Chem Soc (2001) 0.80
Synthesis and biological activity of ras farnesyl protein transferase inhibitors. Tetrapeptide analogs with amino methyl and carbon linkages. Bioorg Med Chem (1994) 0.79
Effects of prolonged ethylene thiourea ingestion on the thyroid of the rat. Food Cosmet Toxicol (1975) 0.79
Effects of short-term administration of ethylenethiourea upon thyroid function of the rat. Bull Environ Contam Toxicol (1972) 0.78
Performance evaluation of a permeable reactive barrier for remediation of dissolved chlorinated solvents in groundwater. J Hazard Mater (1999) 0.78
Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase. J Med Chem (1998) 0.78
2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase. Bioorg Med Chem Lett (2001) 0.77
Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors. J Biol Chem (2001) 0.77
Subchronic effects of guar gum in rats. Food Cosmet Toxicol (1981) 0.76
Long-term toxicity studies of erythrosine. II. Effects on haematology and thyroxine and protein-bound iodine in rats. Food Cosmet Toxicol (1973) 0.76
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett (2001) 0.75
The effects of glaucoma on the latency of the multifocal visual evoked potential. Br J Ophthalmol (2006) 0.75
The risk of redefining rationing. JAMA (1992) 0.75
Otolaryngology. J S C Med Assoc (1995) 0.75
Selective nerve fibre loss in glaucoma: magnocellular or parvocellular. Aust N Z J Ophthalmol (1997) 0.75
Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide. J Med Chem (1989) 0.75
Potential effects of systematic errors in intraocular pressure measurements on screening for ocular hypertension. Eye (Lond) (2013) 0.75
Sulfonylmethanesulfonamide inhibitors of carbonic anhydrase. J Med Chem (1993) 0.75
L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals. Br J Pharmacol (1990) 0.75
Geographical distribution of risk factors and incidence of invasive cervical cancer in south east China. J Epidemiol Community Health (1996) 0.75
Acute severe insulin resistance. A case report. J S C Med Assoc (1973) 0.75
Potent, non-thiol inhibitors of farnesyltransferase. Bioorg Med Chem Lett (1998) 0.75
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase. Bioorg Med Chem Lett (2001) 0.75
Effects of one-year administration of ethylenethiourea upon the thyroid of the rat. J Agric Food Chem (1973) 0.75
Relationship between chronic demyelination of the optic nerve and short term axonal loss. J Neurol Neurosurg Psychiatry (2011) 0.75
Subacute toxicity of toluidine red. Toxicol Appl Pharmacol (1968) 0.75
2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase. J Med Chem (1996) 0.75
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorg Med Chem Lett (2001) 0.75
Triangular wire. J Clin Orthod (2001) 0.75
N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase. J Med Chem (1998) 0.75
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides. J Med Chem (1991) 0.75
Effect of repeat use and coating defects of gold foil electrodes on electroretinogram recording. Vision Res (1995) 0.75
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase. J Med Chem (1999) 0.75
Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett (1999) 0.75
Assessment of disordered eating in females: instrument validation. J Subst Abuse (1992) 0.75
3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferase. Org Lett (2001) 0.75
Diaryl ether inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett (2001) 0.75
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase. Bioorg Med Chem Lett (1999) 0.75
Study of the teratogenic potential of gum arabic. Food Chem Toxicol (1987) 0.75
The neuropathic foot--a management scheme: a case report. Phys Ther (1989) 0.75
Treatment of a strandling whale (Kogia breviceps). N Z Vet J (1984) 0.75
Study of the teratogenic potential of guar gum. Food Chem Toxicol (1987) 0.75
Peribulbar blockade--an alternative anaesthetic 'cocktail'. Aust N Z J Ophthalmol (1992) 0.75
Pseudodipeptide inhibitors of protein farnesyltransferase. J Med Chem (1995) 0.75